PMID- 29427967
OWN - NLM
STAT- MEDLINE
DCOM- 20190409
LR  - 20190409
IS  - 1471-4973 (Electronic)
IS  - 1471-4892 (Linking)
VI  - 40
DP  - 2018 Jun
TI  - Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD.
PG  - 34-38
LID - S1471-4892(17)30142-X [pii]
LID - 10.1016/j.coph.2018.01.002 [doi]
AB  - Diabetes mellitus (DM) is a complex multifactorial disease due to the interaction 
      between environmental noxae and genetic predisposition. Furthermore, an increased 
      association between DM, especially Type 2 diabetes mellitus (T2DM), and the onset 
      of pulmonary function impairment with a bronchial hyperresponsiveness has been 
      documented. DM is a risk factor for accelerated decline in FEV(1) and the 
      development of asthma and COPD. The increased blood glucose concentrations along 
      with higher levels of oxidative stress and inflammation can influence the 
      pulmonary function and, since hypoglycemic drugs can act on these different 
      defects we can hypothesize their direct effect on obstructive pulmonary diseases. 
      Metformin, a biguanide, is the molecule having several evidences of its action on 
      asthma and COPD in patients with T2DM. In this population, Metformin can 
      ameliorate pulmonary outcomes reducing high glucose concentrations, inflammation 
      through the activation of the AMP-activated protein kinase, leading to the 
      decreased production of pro-inflammatory cytokines and blunting allergic 
      eosinophilic airway inflammation. There are evidences of Pioglitazone role on 
      asthma, since the activation of PPARgamma Pioglitazone might inhibit the synthesis 
      and release of pro-inflammatory cytokines. Indeed, Pioglitazone can improve 
      symptoms associated with asthma reducing episodes of exacerbation and oral 
      steroid prescription. Finally, randomized clinical trials using hypoglycemic 
      agents on patients with asthma and COPD with and without DM should be proposed as 
      well as the implementation of a new formulation of hypoglycemic agents to make it 
      possible to administer it via aerosol.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Rogliani, Paola
AU  - Rogliani P
AD  - Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 
      Rome, Italy; Unit of Respiratory Medicine, University Hospital 'Fondazione 
      Policlinico di Tor Vergata', Rome, Italy. Electronic address: 
      paola.rogliani@uniroma2.it.
FAU - Ora, Josuel
AU  - Ora J
AD  - Unit of Respiratory Medicine, University Hospital 'Fondazione Policlinico di Tor 
      Vergata', Rome, Italy.
FAU - Di Daniele, Nicola
AU  - Di Daniele N
AD  - Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
FAU - Lauro, Davide
AU  - Lauro D
AD  - Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; Unit 
      of Endocrinology, Diabetes Mellitus and Metabolic Diseases, University Hospital 
      'Fondazione Policlinico di Tor Vergata', Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180209
PL  - England
TA  - Curr Opin Pharmacol
JT  - Current opinion in pharmacology
JID - 100966133
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Animals
MH  - Anti-Asthmatic Agents/adverse effects/*therapeutic use
MH  - Anti-Inflammatory Agents/adverse effects/*therapeutic use
MH  - Asthma/*drug therapy/epidemiology/metabolism/physiopathology
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Lung/*drug effects/metabolism/physiopathology
MH  - Pulmonary Disease, Chronic Obstructive/*drug 
      therapy/epidemiology/metabolism/physiopathology
EDAT- 2018/02/11 06:00
MHDA- 2019/04/10 06:00
CRDT- 2018/02/11 06:00
PHST- 2018/01/03 00:00 [received]
PHST- 2018/01/21 00:00 [accepted]
PHST- 2018/02/11 06:00 [pubmed]
PHST- 2019/04/10 06:00 [medline]
PHST- 2018/02/11 06:00 [entrez]
AID - S1471-4892(17)30142-X [pii]
AID - 10.1016/j.coph.2018.01.002 [doi]
PST - ppublish
SO  - Curr Opin Pharmacol. 2018 Jun;40:34-38. doi: 10.1016/j.coph.2018.01.002. Epub 
      2018 Feb 9.